Key result
NSAID and low-dose aspirin therapy are associated with upper and lower gastrointestinal complications, which can be managed with gastroprotective pharmacotherapy and H. pylori eradication.
Why the study?
What are the gastrointestinal risks associated with NSAID and low-dose aspirin therapy, and what is the efficacy of current risk management strategies?
What are the gastrointestinal risks associated with NSAID and low-dose aspirin therapy, and what is the efficacy of current risk management strategies?
This review highlights the serious gastrointestinal risks of NSAID and low-dose aspirin therapy and discusses strategies to mitigate these risks.
Answers are grounded in this paper and cite their sources.
May support gastroprotective strategies in NSAID/aspirin users; leaves open optimal regimens pending prospective trials.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin is accompanied by risk of upper and lower gastrointestinal (GI) complications, some of which can be serious or even fatal. Management strategies to reduce this risk include gastroprotective pharmacotherapy, use of safer NSAIDs, and eradication of Helicobacter pylori infection. In this article, Dr Lanas summarizes the GI risks associated with NSAID and low-dose aspirin therapy and weighs the efficacy of current risk management strategies.
No takes yet. Share an insight, caveat, or question.
Ángel Lanas (2005) conducted a review in Gastrointestinal complications. NSAIDs and low-dose aspirin was evaluated. NSAID and low-dose aspirin therapy are associated with upper and lower gastrointestinal complications, which can be managed with gastroprotective pharmacotherapy and H. pylori eradication.
Synapse has enriched 10 related papers. Consider them for comparative context: